HEPAR Primary: Holmium-166-radioembolization in Hepatocellular Carcinoma Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 21, 2017

Primary Completion Date

January 1, 2020

Study Completion Date

August 1, 2021

Conditions
Hepatocellular CarcinomaHepatocellular Carcinoma Non-resectable
Interventions
DEVICE

Holmium-166 radioembolization

An intra-arterial radioembolization procedure will be performed. The hepatic artery catheter is inserted via the femoral or radial artery under x-ray guidance by a trained interventional radiologist. The radiologist must repeatedly check the position of the catheter during the procedure to ensure it remains correctly sited and that reflux of the QuiremSpheres® into other organs does not occur. This is performed by injecting contrast medium. At the conclusion of the procedure, the catheter is removed.

Trial Locations (2)

3015CN

Erasmus Medical Center, Rotterdam

3584 CX

University Medical Center Utrecht, Utrecht

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Dutch Cancer Society

OTHER

collaborator

Erasmus Medical Center

OTHER

collaborator

Quirem Medical B.V.

INDUSTRY

lead

UMC Utrecht

OTHER

NCT03379844 - HEPAR Primary: Holmium-166-radioembolization in Hepatocellular Carcinoma Patients | Biotech Hunter | Biotech Hunter